A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12)

A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12)

Item

http://www.wikidata.org/entity/Q33618145

Q33618145

about

RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.Genomic index of sensitivity to endocrine therapy for breast cancer.Standard of care and promising new agents for triple negative metastatic breast cancer Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Defining breast cancer intrinsic subtypes by quantitative receptor expression.Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer.Clinicopathological characteristics and optimal management for esophagogastric junctional cancer; a single center retrospective cohort study.Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort.Optimal adjuvant endocrine therapy for early breast cancer.Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.The importance of nonpharmacogenetic factors in endocrine therapy.Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EB Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinica The prognostic effects of somatic mutations in ER-positive breast cancer

P2860

Q27852757-E47FA3F4-B25A-4A5D-A445-F3ECFC98B345 Q34193932-9E7BA9F9-C34C-44FB-A6D6-D728FCAE9A82 Q34774884-50216815-0E50-459B-88AC-F9700E62C11A Q35186747-6FA8ADDF-040B-4B33-964C-7CB061439205 Q35586697-BF8AF4AA-4F94-40A9-BC84-E9B0624E041C Q36292773-C4C8196D-B1EF-4F00-B985-3B0D8D90165E Q36575789-2C3B193B-42F1-4F0E-894C-A212F79FD09C Q36630430-BFDE44E5-4DD3-49A1-B914-462635C8B8DA Q37095809-4E1840EB-53FD-4CAA-9F10-80717D1AF1A2 Q37689699-7CF94118-FADA-46C1-97D2-609B59445A02 Q37738877-6E724321-A4E4-4B64-B634-0E2D952BA0DA Q37830371-5705EBF5-AAE3-4BE3-908D-E395C36D3AD2 Q37992403-D408519B-C8DD-4272-AC3B-779CED09102B Q38003706-54C2F946-0615-47AC-A138-BB6D3F66C91D Q38853194-5CF7B1CF-86CD-456D-811C-0A5A79CBE36A Q43738086-1313BD40-1C34-44F8-A07C-812191666894 Q44898498-228F5737-6ADB-4EB6-99E0-6A21F8D59323 Q58765339-63D3F929-B0A8-4F77-9154-8A66C50C4AEF

P2860

A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12)

Item

http://www.wikidata.org/entity/Q33618145

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu